Ansbert Gadicke
CIK: 0001134655
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (35 total)
- Jan 12, 2026AKTS
Aktis Oncology, Inc.
Purchase(P)Indirect1.1M shares at avg. $18.00$20.0M - Jan 12, 2026AKTS
Aktis Oncology, Inc.
Conversion(C)Indirect1.3M shares- - Jan 12, 2026AKTS
Aktis Oncology, Inc.
Conversion(C)Indirect5.9M shares- - Jan 12, 2026AKTS
Aktis Oncology, Inc.
Conversion(C)Indirect1.6M shares- - Dec 4, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect83.2K shares at avg. $0.97$81K - Dec 3, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect57.2K shares at avg. $0.87$50K - Dec 2, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect59.3K shares at avg. $0.89$53K - Dec 1, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect60.9K shares at avg. $0.94$57K - Nov 28, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect20.3K shares at avg. $0.99$20K - Nov 26, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect60.7K shares at avg. $0.98$60K - Nov 25, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect42.5K shares at avg. $0.92$39K - Nov 24, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect88.8K shares at avg. $0.98$87K - Nov 21, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect64.3K shares at avg. $0.83$53K - Nov 20, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect41.2K shares at avg. $0.89$37K - Nov 19, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect66.3K shares at avg. $0.94$62K - Nov 18, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect52.6K shares at avg. $0.93$49K - Nov 17, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect57.1K shares at avg. $0.95$54K - Nov 14, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect61.6K shares at avg. $0.93$57K - Nov 13, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect91K shares at avg. $0.98$89K - Nov 12, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect40.7K shares at avg. $1.09$44K - Nov 11, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect55.8K shares at avg. $1.14$64K - Nov 10, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect48.6K shares at avg. $1.18$57K - Nov 7, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect68.5K shares at avg. $1.11$76K - Nov 6, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect54.5K shares at avg. $1.21$66K - Nov 5, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect48K shares at avg. $1.22$58K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 12, 2026 |  AKTS Aktis Oncology, Inc. | Purchase(P) | 1,112,777 | $18.00 | $20,029,986 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Conversion(C) | 1,314,262 | - | $0 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Conversion(C) | 5,914,197 | - | $0 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Conversion(C) | 1,577,119 | - | $0 | Indirect |
| Dec 4, 2025 |  HOWL Werewolf Therapeutics, Inc. | Sale(S) | 83,230 | $0.97 | $80,733 | Indirect |
| Dec 3, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 57,225 | $0.87 | $49,786 | Indirect |
| Dec 2, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 59,277 | $0.89 | $52,757 | Indirect |
| Dec 1, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 60,917 | $0.94 | $57,262 | Indirect |
| Nov 28, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 20,277 | $0.99 | $20,074 | Indirect |
| Nov 26, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 60,733 | $0.98 | $59,518 | Indirect |
| Nov 25, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 42,533 | $0.92 | $39,130 | Indirect |
| Nov 24, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 88,802 | $0.98 | $87,026 | Indirect |
| Nov 21, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 64,331 | $0.83 | $53,395 | Indirect |
| Nov 20, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 41,152 | $0.89 | $36,625 | Indirect |
| Nov 19, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 66,324 | $0.94 | $62,345 | Indirect |
| Nov 18, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 52,627 | $0.93 | $48,943 | Indirect |
| Nov 17, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 57,061 | $0.95 | $54,208 | Indirect |
| Nov 14, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 61,640 | $0.93 | $57,325 | Indirect |
| Nov 13, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 90,951 | $0.98 | $89,132 | Indirect |
| Nov 12, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 40,669 | $1.09 | $44,329 | Indirect |
| Nov 11, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 55,810 | $1.14 | $63,623 | Indirect |
| Nov 10, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 48,570 | $1.18 | $57,313 | Indirect |
| Nov 7, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 68,480 | $1.11 | $76,013 | Indirect |
| Nov 6, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 54,452 | $1.21 | $65,887 | Indirect |
| Nov 5, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 47,950 | $1.22 | $58,499 | Indirect |
1-25 of 35 transactions
About GADICKE ANSBERT
GADICKE ANSBERT (SEC CIK 0001134655) files insider reports with the SEC as 10% Owner of Aktis Oncology, Inc. (AKTS), 10% Owner of Werewolf Therapeutics, Inc. (HOWL) and iTeos Therapeutics, Inc. (ITOS).
Signal8 holds 13 ownership filings by GADICKE ANSBERT (1 Form 3, 12 Form 4), filed between Apr 30, 2025 and Jan 14, 2026. Those filings report 35 transactions, from Mar 27, 2025 to Jan 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GADICKE ANSBERT's filings is in BOSTON, MA.
Recent filings by GADICKE ANSBERT
- Jan 12, 2026: Open-market purchase of AKTS shares (Form 4, code P).
- Jan 12, 2026: Conversions of AKTS shares (3 lines, Form 4, code C).
- Dec 4, 2025: Open-market sale of HOWL shares (Form 4, code S).
- Dec 3, 2025: Open-market sale of HOWL shares (Form 4, code S).
- Dec 2, 2025: Open-market sale of HOWL shares (Form 4, code S).
Other insiders filing for Aktis Oncology, Inc. (AKTS)
- Czibere Akos, Chief Medical Officer
- Herrmann Ken, Director
- Ron-Bigger Shulamit, Chief Operating Officer
- Gormley Glenn, Director
- ELI LILLY & Co, 10% Owner
- Foley Todd, Director